ID: ALA550657

Max Phase: Preclinical

Molecular Formula: C16H19FN2O4

Molecular Weight: 322.34

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(=O)Nc1cc(F)c(C(=O)O)cc1NC(=O)C1CCCCC1

Standard InChI:  InChI=1S/C16H19FN2O4/c1-9(20)18-14-8-12(17)11(16(22)23)7-13(14)19-15(21)10-5-3-2-4-6-10/h7-8,10H,2-6H2,1H3,(H,18,20)(H,19,21)(H,22,23)

Standard InChI Key:  QYPSVNXZUYHQOR-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 322.34

Molecular Weight (Monoisotopic): 322.1329

AlogP: 3.00

#Rotatable Bonds: 4

Polar Surface Area: 95.50

Molecular Species: ACID

HBA: 3

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.25

CX Basic pKa:

CX LogP: 2.36

CX LogD: -1.07

Aromatic Rings: 1

Heavy Atoms: 23

QED Weighted: 0.79

Np Likeness Score: -1.33

References

1. Magesh S, Savita V, Moriya S, Suzuki T, Miyagi T, Ishida H, Kiso M..  (2009)  Human sialidase inhibitors: design, synthesis, and biological evaluation of 4-acetamido-5-acylamido-2-fluoro benzoic acids.,  17  (13): [PMID:19450982] [10.1016/j.bmc.2009.04.065]

Source

Source(1):

• Scientific Literature